BioPharmSignal logoBioPharmSignal

Biotech News

Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025

Orchard Therapeutics (ORTX)Orchard TherapeuticsCompany update

LENMELDY™ is the first and only disease-modifying intravenous infusion proven to extend life expectancy in pre-symptomatic late infantile (PSLI) patients and mitigate the cognitive and/or physical impact of early-onset MLD Six accepted abstracts at ASGCT 2025 detail the therapeutic potential of HSC

Related news

ORTXOrchard Therapeutics2025-02-12 12:01 EST

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

ORTXOrchard Therapeutics2025-02-03 13:45 EST

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™

View all latest news

Orchard Therapeutics

Orchard Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ORTXOrchard Therapeutics2025-12-16 17:15 EST

Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel

ORTXOrchard Therapeutics2025-10-28 06:00 EST

Kyowa Kirin and Orchard Therapeutics Announce OTL-200 Granted Orphan Regenerative Medicine Product Designation for Early-onset MLD in Japan

ORTXOrchard Therapeutics2025-07-07 11:00 EST

Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome

ORTXOrchard Therapeutics2025-05-13 11:01 EST

Orchard Therapeutics Announces New England Journal of Medicine Publication of Long-term Clinical Outcomes from its HSC Gene Therapy for MLD and Multiple Presentations at ASGCT 2025

ORTXOrchard Therapeutics2025-02-12 12:01 EST

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States